1. Home
  2. PDX vs GERN Comparison

PDX vs GERN Comparison

Compare PDX & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PDX
  • GERN
  • Stock Information
  • Founded
  • PDX 2019
  • GERN 1990
  • Country
  • PDX NY
  • GERN United States
  • Employees
  • PDX N/A
  • GERN N/A
  • Industry
  • PDX Finance/Investors Services
  • GERN Biotechnology: Pharmaceutical Preparations
  • Sector
  • PDX Finance
  • GERN Health Care
  • Exchange
  • PDX Nasdaq
  • GERN Nasdaq
  • Market Cap
  • PDX 996.5M
  • GERN 823.0M
  • IPO Year
  • PDX N/A
  • GERN 1996
  • Fundamental
  • Price
  • PDX $21.95
  • GERN $1.08
  • Analyst Decision
  • PDX
  • GERN Buy
  • Analyst Count
  • PDX 0
  • GERN 7
  • Target Price
  • PDX N/A
  • GERN $3.00
  • AVG Volume (30 Days)
  • PDX N/A
  • GERN 8.4M
  • Earning Date
  • PDX 01-01-0001
  • GERN 11-05-2025
  • Dividend Yield
  • PDX 4.95%
  • GERN N/A
  • EPS Growth
  • PDX N/A
  • GERN N/A
  • EPS
  • PDX N/A
  • GERN N/A
  • Revenue
  • PDX N/A
  • GERN $183,403,000.00
  • Revenue This Year
  • PDX N/A
  • GERN $166.20
  • Revenue Next Year
  • PDX N/A
  • GERN $55.83
  • P/E Ratio
  • PDX N/A
  • GERN N/A
  • Revenue Growth
  • PDX N/A
  • GERN 522.13
  • 52 Week Low
  • PDX $13.52
  • GERN $1.04
  • 52 Week High
  • PDX $21.05
  • GERN $4.50
  • Technical
  • Relative Strength Index (RSI)
  • PDX 30.33
  • GERN 31.93
  • Support Level
  • PDX $22.07
  • GERN $1.04
  • Resistance Level
  • PDX $22.52
  • GERN $1.29
  • Average True Range (ATR)
  • PDX 0.36
  • GERN 0.06
  • MACD
  • PDX 0.06
  • GERN -0.02
  • Stochastic Oscillator
  • PDX 40.68
  • GERN 12.96

About PDX PIMCO Dynamic Income Strategy Fund of Beneficial Interest

PIMCO Dynamic Income Strategy Fund is a non-diversified, limited-term, closed-end management investment company. It seeks current income as a primary objective and capital appreciation as a secondary objective. The fund makes investments using a dynamic asset allocation plan among multiple sectors in the public and private credit markets globally, including corporate debt, mortgage-related and other asset-backed instruments, government and sovereign debt, taxable municipal bonds, and other fixed, variable, and floating-rate income-producing securities of U.S. and foreign issuers, including emerging market issuers and real estate-related investments.

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Share on Social Networks: